What is Avanos Medical's granted (in shares)?

Avanos Medical (AVNS) reported granted (in shares) of 288K in Q4 2025.

What does granted (in shares) mean?

The total number of stock option shares granted to employees and directors during the reporting period. This metric provides insight into the company's equity-based incentive strategy and potential future dilution.

Avanos Medical AVNS Granted (in shares)

Granted (in shares) at other companies

Baxter InternationalBAX

1.3M—

Option Care Health, Inc.OPCH

0—

ScansourceSCSC

0—

CorvelCRVL

83K—

Charles River LaboratoriesCRL

21K—

Henry ScheinHSIC

177.1K—

Other financials

Income statement

See full

Revenue$182.2M+8.8%

Gross profit$94.2M+4.9%

Operating income$8.9M-13.6%

Net income$5.1M-22.7%

EPS (diluted)$0.11-21.4%

Balance sheet

See full

Cash & equivalents$65.6M-32.4%

Total debt$138.4M-1.8%

Total equity$782.1M-6.8%

Total assets$1.1B-5.2%

Cash flow

See full

Operating cash flow-$12.3M-148%

CapEx$4.3M-35.8%

Free cash flow-$16.6M-187%

Valuation

See full

Market cap$1.17B+108%

Enterprise value$1.24B+105%

P/S1.6×+0.8×

Profitability

See full

Gross margin50%-4.6pp

Operating margin-9.1%-4.2pp

Net margin-10.4%-4.7pp

FCF margin1.6%-14.9pp

Returns & leverage

See full

Return on equity-9.2%-3.9pp

Debt / equity0.2×0.0×

Current ratio2.5×-0.1×

Where this comes from

Reported directly by Avanos Medical in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.

The official record: Avanos Medical’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avanos Medical's granted (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Avanos Medical's granted (in shares)?: Avanos Medical (AVNS) reported granted (in shares) of 288K in Q4 2025.
What does granted (in shares) mean?: The total number of stock option shares granted to employees and directors during the reporting period. This metric provides insight into the company's equity-based incentive strategy and potential future dilution.